Responses
Clinical/translational cancer immunotherapy
Original research
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
Compose a Response to This Article
Other responses
No responses have been published for this article.